In future studies, it would be of interest to investigate drugs that target pathways other than the VEGF/VEGFR axis (for instance inhibition of the FGF signaling pathway), drugs other than antibodies (such as tyrosine kinase inhibitors), and also drug combinations that have demonstrated efficacy in other cancer entities [19]. Here, KDR is linked to cancer.